PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.
The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.
How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.